Paul Liberator
Overview
Explore the profile of Paul Liberator including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu Y, Yurgelonis I, Noell S, Yang Q, Guan S, Li Z, et al.
Sci Adv
. 2024 Jul;
10(30):eadl4013.
PMID: 39047088
To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M inhibitor nirmatrelvir (Paxlovid...
2.
Hao L, Kuttel M, Ravenscroft N, Thompson A, Prasad A, Gangolli S, et al.
Vaccine
. 2022 Jul;
40(33):4872-4880.
PMID: 35810060
Protection conferred by pneumococcal polysaccharide conjugate vaccines (PCVs) is associated with PCV-induced antibodies against vaccine-covered serotypes that exhibit functional opsonophagocytic activity (OPA). Structural similarity between capsular polysaccharides of closely related...
3.
Findlow J, Borrow R, Stephens D, Liberator P, Anderson A, Balmer P, et al.
Expert Rev Vaccines
. 2022 Apr;
21(6):753-769.
PMID: 35469524
Introduction: The two currently licensed surface protein non-capsular meningococcal serogroup B (MenB) vaccines both have the purpose of providing broad coverage against diverse MenB strains. However, the different antigen compositions...
4.
Thomas S, Moreira Jr E, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.
N Engl J Med
. 2021 Sep;
385(19):1761-1773.
PMID: 34525277
Background: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease...
5.
Liberator P, Donald R, Balmer P, Findlow J, Anderson A
Front Microbiol
. 2020 Nov;
11:538209.
PMID: 33240223
No abstract available.
6.
Apgar J, Wilkening R, Parker Jr D, Meng D, Wildonger K, Sperbeck D, et al.
Bioorg Med Chem Lett
. 2020 Nov;
32:127661.
PMID: 33160023
We previously reported medicinal chemistry efforts that identified MK-5204, an orally efficacious β-1,3-glucan synthesis inhibitor derived from the natural product enfumafungin. Further extensive optimization of the C2 triazole substituent identified...
7.
Findlow J, Bayliss C, Beernink P, Borrow R, Liberator P, Balmer P
Vaccine
. 2020 Sep;
38(49):7716-7727.
PMID: 32878710
Neisseria meningitidis, the causative agent of invasive meningococcal disease (IMD), is classified into different serogroups defined by their polysaccharide capsules. Meningococcal serogroups A, B, C, W, and Y are responsible...
8.
Apgar J, Wilkening R, Parker Jr D, Meng D, Wildonger K, Sperbeck D, et al.
Bioorg Med Chem Lett
. 2020 Aug;
30(17):127357.
PMID: 32738971
Our previously reported efforts to produce an orally active β-1,3-glucan synthesis inhibitor through the semi-synthetic modification of enfumafungin focused on replacing the C2 acetoxy moiety with an aminotetrazole and the...
9.
Li Z, Lee K, Rajyaguru U, Jones C, Janezic S, Rupnik M, et al.
Front Microbiol
. 2020 Jul;
11:1310.
PMID: 32636819
() is the most commonly recognized cause of infectious diarrhea in healthcare settings. Currently there is no vaccine to prevent initial or recurrent infection (CDI). Two large clostridial toxins, TcdA...
10.
Bettinger J, Liberator P, Halperin S, Vaudry W, Sadarangani M, Hao L, et al.
Vaccine
. 2020 Jan;
38(8):2026-2033.
PMID: 31983586
Background: Invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) remains a health risk in Canada and globally. Two MenB vaccines are now approved for use. An understanding of...